{"nctId":"NCT01248793","briefTitle":"Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis","startDateStruct":{"date":"2010-10"},"conditions":["Ankylosing Spondylitis"],"count":213,"armGroups":[{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Golimumab (placebo group)"]},{"label":"Golimumab","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Golimumab","otherNames":[]},{"name":"Golimumab (placebo group)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Have a diagnosis of definite akylosing spondylitis for at least 3 months\n\n* Have symptoms of active disease at screening and at baseline\n* no active infections\n\nExclusion Criteria:\n\n* Have other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy\n* Have complete ankylosis of the spine\n* Have a history of latent or active granulomatous infection\n* Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14","description":"Number of patients who achieved a \\>= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 24","description":"Number of patients who achieved a \\>= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14","description":"BASFI is a participant's self-assessment, represented as a mean (Visual Analogue Scale \\[Score\\]; 0 cm \\[easy\\] to 10 cm \\[impossible\\]) of 10 questions, 8 of which relate to the participant's functional anatomy and 2 of which relate to a participant's ability to cope with everyday life. A negative change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.113","spread":"2.0967"},{"groupId":"OG001","value":"-1.262","spread":"2.5698"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14","description":"BASMI is a combined score of 5 components of spine flexibility, ranging from 0 (least impairment) to 10 (most impairment). A negative change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.718"},{"groupId":"OG001","value":"-0.42","spread":"0.906"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":103},"commonTop":["Upper Respiratory Tract Infection","Liver Function Test Abnormal","Alanine Aminotransferase Increased","Transaminases Increased"]}}}